Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.

Read full article (External website)

1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply